Alnylam Pharmaceuticals (ALNY) Current Assets (2009 - 2026)

Alnylam Pharmaceuticals has reported Current Assets for 18 years, with the latest figure at $4.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 29.1% year-over-year to $4.2 billion; the trailing twelve-month figure through Mar 2026 stood at $4.2 billion (up 29.1% YoY), and the FY2025 full-year result was $4.1 billion, up 22.92% from the prior year.
• Current Assets for Q1 2026 stood at $4.2 billion, up from $4.1 billion in the prior quarter.
• The five-year high for Current Assets was $4.2 billion in Q1 2026, with the low at $2.5 billion in Q2 2022.
• Historically, Current Assets has averaged $3.1 billion across 5 years, with a median of $3.0 billion in 2024.
• Annual changes were most pronounced in 2022 — Current Assets decreased 9.3% — and 2026, when it rose 29.1%.
• Alnylam Pharmaceuticals' Current Assets stood at $2.7 billion in 2022, then climbed by 10.79% to $3.0 billion in 2023, then rose by 10.48% to $3.3 billion in 2024, then advanced by 22.92% to $4.1 billion in 2025, then climbed by 4.16% to $4.2 billion in 2026.
• The last three Current Assets figures came in at $4.2 billion (Q1 2026), $4.1 billion (Q4 2025), and $4.0 billion (Q3 2025), per Business Quant data.